Ovarian Cancer Clinical Trials in Chicago

Showing 221-224 of 224 trials

ABT-751 in Treating Young Patients With Refractory Solid Tumors

NCT00036959

RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects of ABT-751 in treating young patients with refractory solid tumors.

Brain and Central Nervous System TumorsChildhood Germ Cell TumorExtragonadal Germ Cell Tumor+6 more

National Institutes of Health Clinical Center (CC)90 participantsStarted Mar 2002

Chicago, Illinois, United States • Bethesda, Maryland, United States • Philadelphia, Pennsylvania, United States

TERMINATEDPhase 22.2 miles

Study of XL999 in Patients With Previously Treated Ovarian Cancer

NCT00277290

This clinical trial is being conducted at multiple sites to evaluate the activity, safety, and tolerability of XL999 when given weekly to patients with ovarian cancer that has previously been treated with platinum-based chemotherapy. XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Ovarian Cancer

Symphony Evolution, Inc.24 participantsStarted Jan 2006

Greenbrae, California, United States • Port Saint Lucie, Florida, United States • Chicago, Illinois, United States +6 more locations

ABT-751 in Treating Young Patients With Refractory Solid Tumors

Study of XL999 in Patients With Previously Treated Ovarian Cancer

Ovarian Cancer Trials in Other Cities

Clinical Trial for Ovarian Cancer (OvaRex®)

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

Other Conditions in Chicago